Val
—
Gro
—
Qua
—
Mom
—
Sta
—
Cap—
P/S25.80
P/E—
Fwd P/E-32.22
PEGN/A
52W— – —
RSI—
Target$119.56 (-17.0%)
Beta1.11
Div—
Loading chart…
RSI ()
Loading patterns…
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products, including propionic and methylmalonic acidemia, and cystic fibrosis. It has strategic alliances and collaborations with Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; immatics N.V.; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Signal
Trend Strength
Price Levels
52-Week Range
52W Low
—
52W High
Position in Range
—
RSI (14)
0 · Oversold
RSI 61
Overbought · 100
Signal
Neutral
EMA Price Levels
Activity & Patterns
Volume Analysis
Momentum Dashboard
Detected Patterns
4Bullish
3Bearish
0Neutral
Key Signals 1
▲ Double Bottom
Major reversal
2026-06-04 · $49.26
Two lows ~$44.76 — bullish reversal confirmed
Learn more →
Momentum Signals 6
▲ MACD Bullish Crossover
▲ MACD Bullish Crossover
▲ MACD Bullish Crossover
▼ MACD Bearish Crossover
View overlays on the price chart via Overview tab → Pattern Overlays.
EPS — History & Forecast
Estimate
Beat
Miss
Forecast
Loading…
Revenue — History & Forecast
Revenue
Forecast
Loading…
EPS Beat Rate
88%
7/8 quarters
Wall Street Consensus
HOLD
BuyHoldSell
Price Target Range
$119.56
-17.0% upside
Low $45
—
High $170
Consensus
Current price
Wall Street Analyst Ratings
Sort by
| Firm | Rating | Change | Action | Date |
|---|
Profitability
Gross Margin
-66.02%Last 12 Months
Operating Margin
-557.93%Last 12 Months
Return on Equity
-39.00%Last 12 Months
Revenue Growth
2.10%Year over Year
Free Cash Flow
299.25MLast 12 Months
Free Cash Flow Yield
—Last 12 Months
Balance Sheet
Debt / Equity
19.04Most Recent Quarter
Current Ratio
2.29Most Recent Quarter
Cash
5.14BMost Recent Quarter
Total Debt
1.29BMost Recent Quarter
Net Debt
—Most Recent Quarter
How MRNA Makes Its Money
Cash Flow Breakdown
Quarterly Metrics
| Quarter | Revenue | Rev YoY | Gross Profit | Op. Income | Net Income | Net YoY | Gross % | Op % | Net % |
|---|
Full Key Statistics
Valuation
| Market Cap | 57.48B |
| Enterprise Value | 53.63B |
| Trailing P/E | N/A |
| Forward P/E | -32.22 |
| PEG Ratio (5yr) | N/A |
| Price/Sales (ttm) | 25.80 |
| Price/Book (mrq) | 8.50 |
| EV/Revenue | 24.07 |
| EV/EBITDA | -24.43 |
Share Statistics
| Avg Vol (3m) | 16.11M |
| Shares Outstanding | 399.24M |
| Float | 372.26M |
| % Held by Insiders | 7.32% |
| % Held by Institutions | 80.45% |
| Short Ratio | 1.36 |
| Short % of Float | 11.98% |
Profitability
| Gross Margin | -66.02% |
| Operating Margin (ttm) | -557.93% |
| Profit Margin | -141.43% |
| Return on Assets (ttm) | -13.26% |
| Return on Equity (ttm) | -39.00% |
Income Statement
| Revenue (ttm) | 2.23B |
| Revenue Growth (yoy) | 2.10% |
| Gross Profit (ttm) | -1.47B |
| EBITDA | -2.20B |
| Net Income (ttm) | -3.15B |
| Diluted EPS (ttm) | -8.41 |
| EPS Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 5.14B |
| Total Debt (mrq) | 1.29B |
| Debt / Equity (mrq) | 19.04 |
| Current Ratio (mrq) | 2.29 |
| Book Value / Share | 16.95 |
| Operating CF (ttm) | -1.07B |
| Free Cash Flow (ttm) | 299.25M |
Trading & Dividends
| Beta (5Y) | 1.11 |
| 50-Day MA | 89.61 |
| 200-Day MA | 56.53 |
| Fwd Dividend Yield | N/A |
| Payout Ratio | 0.00% |
No dividend history available for MRNA.
Ownership Breakdown
Institutional 80.45%
Insider 7.32%
Public 12.2%
Short Interest
11.98% of float
High
Institutional 13F Holdings
Famous investors who disclosed a position in MRNA in their latest SEC 13F filing.
Loading…
Insider Transactions
| Date | Insider | Role | Transaction | Shares | Price | Value |
|---|